Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses
Patent No. EP3370770 (titled "Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses") was filed by Janssen Biotech on Nov 1, 2016. The application was issued on Jan 20, 2021.
Patent Summary
Subcutaneous injection of anti-CD38 antibodies for treating cancers like multiple myeloma, using a hyaluronidase enzyme to reduce viscosity and improve tissue penetration. The composition contains an anti-CD38 antibody at 20 mg/mL concentration and a hyaluronidase like rHuPH20 at 500 U/mL. The hyaluronidase helps the subcutaneous injection reach deeper tissues by breaking down hyaluronic acid in the extracellular matrix.
Patent Family
Patent Oppositions (5)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents
EP3370770
- Application Number
- EP16862791A
- Filing Date
- Nov 1, 2016
- Status
- Revoked
- Jan 22, 2025
- Publication Date
- Jan 20, 2021
- External Links
- Slate, Register , Google Patents